Marker Therapeutics (NASDAQ:MRKR) vs. Madrigal Pharmaceuticals (NASDAQ:MDGL) Head to Head Comparison

Madrigal Pharmaceuticals (NASDAQ:MDGL) and Marker Therapeutics (NASDAQ:MRKR) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, risk, institutional ownership, valuation, dividends and profitability.

Profitability

This table compares Madrigal Pharmaceuticals and Marker Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Madrigal Pharmaceuticals	-25.32%	-56.65%	-25.53%
Marker Therapeutics	N/A	-56.96%	-47.82%

Analyst Ratings

This is a breakdown of recent recommendations for Madrigal Pharmaceuticals and Marker Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Madrigal Pharmaceuticals	1	2	13	1	2.82
Marker Therapeutics	1	0	2	1	2.75

Madrigal Pharmaceuticals currently has a consensus target price of $706.87, indicating a potential upside of 76.88%. Marker Therapeutics has a consensus target price of $10.00, indicating a potential upside of 1,020.07%. Given Marker Therapeutics’ higher probable upside, analysts clearly believe Marker Therapeutics is more favorable than Madrigal Pharmaceuticals.

Valuation & Earnings

This table compares Madrigal Pharmaceuticals and Marker Therapeutics”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Madrigal Pharmaceuticals	$958.40 million	9.63	-$288.28 million	($5.98)	-66.83
Marker Therapeutics	$3.55 million	4.19	-$12.16 million	($0.41)	-2.18

Marker Therapeutics has lower revenue, but higher earnings than Madrigal Pharmaceuticals. Madrigal Pharmaceuticals is trading at a lower price-to-earnings ratio than Marker Therapeutics, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

98.5% of Madrigal Pharmaceuticals shares are owned by institutional investors. Comparatively, 22.4% of Marker Therapeutics shares are owned by institutional investors. 17.6% of Madrigal Pharmaceuticals shares are owned by company insiders. Comparatively, 5.7% of Marker Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Risk & Volatility

Madrigal Pharmaceuticals has a beta of -0.98, meaning that its stock price is 198% less volatile than the S&P 500. Comparatively, Marker Therapeutics has a beta of 1.65, meaning that its stock price is 65% more volatile than the S&P 500.

Summary

Madrigal Pharmaceuticals beats Marker Therapeutics on 8 of the 14 factors compared between the two stocks.

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.

About Marker Therapeutics

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia; and MT-601 to treat lymphoma and pancreatic cancer. Marker Therapeutics, Inc. is headquartered in Houston, Texas.